Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15085312 | 0.84 | POLB (0.45) | ALDH1A1HSP90AA1PPARGFFAR1MEN1 | |
| SCHEMBL16450276 | 0.82 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1KDM4EMEN1GAA | |
| SCHEMBL15085313 | 0.81 | KDM4E (0.40) | MAPK1NQO2MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL16844577 | 0.77 | TSHR (0.40) | ALDH1A1PPARGHTR2AMEN1GAA | |
| SCHEMBL1477578 | 0.77 | TSHR (0.50) | MAPK1KDM4EMAPT | |
| SCHEMBL1477389 | 0.77 | TSHR (0.50) | MAPK1KDM4EMAPT | |
| SCHEMBL22209851 | 0.77 | TSHR (0.50) | MAPK1KDM4EMAPT | |
| SCHEMBL12749371 | 0.77 | TSHR (0.50) | MAPK1KDM4EMAPT | |
| SCHEMBL30280677 | 0.77 | TSHR (0.50) | MAPK1KDM4EMAPT | |
| SCHEMBL1478163 | 0.75 | CYP19A1 (0.51) | NQO2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124472-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2017-02-01 | — | — | EP | disclosed |
| US-20160206621-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2016-07-21 | — | — | US | disclosed |
| EP-2797888-B1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE LTD (KY) | 2016-06-08 | — | — | EP | disclosed |
| US-9273046-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2016-03-01 | — | — | US | disclosed |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2015-02-12 | — | — | US | disclosed |
| WO-2013097224-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206621-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | BRD4 908/4885MAPK1 224/4885SMN1; SMN2 4831/4885 |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | BRD4 908/4885MAPK1 224/4885SMN1; SMN2 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.